Compare AbCellera Biologics Inc (ABCL) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Global Payments Inc — how do they compare? AbCellera Biologics Inc trades at $9.94 (market cap $2.99B), while Global Payments Inc trades at $84.82 (market cap $22.72B). The key difference: Global Payments Inc is far larger — about 7.6× AbCellera Biologics Inc's market cap, and Global Payments Inc pays a 1.16% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GPN | |
|---|---|---|
Market Cap | $2.99B | $22.72B |
Sector | Health | Industrials |
52-Week High | $9.76 | $90.01 |
52-Week Low | $2.78 | $62.47 |
Enterprise Value | $2.58B | $40.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Global Payments (GPN) trades at $86.13, up slightly by 0.01% today, with a bullish technical signal from moving averages and strong quarterly EPS beats. The company reported Q2 2026 EPS of $3.46, exceeding expectations, but faces headwinds with a negative net income margin of -9.15% in 2026. Recent news highlights Genius platform momentum driving earnings growth, though full-year revenue guidance was trimmed due to Middle East challenges.
Outlook remains cautiously optimistic with a consensus price target of $96.67, offering 12% upside, supported by analyst buy ratings at 58.7%. Key risks include margin pressure from rising costs and intense fintech competition, while institutional interest persists with recent investments like Delta Global Management's $1.74 million stake in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
